About Avanir
Avanir is a company based in Aliso Viejo (United States) founded in 1988 was acquired by Otsuka in December 2014. Avanir operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
- Headquarter Aliso Viejo, United States
- SectorsHealthcare
- Website avanir.com
- Social LinkedIn
- Acquired by Otsuka (Dec 2014)
- Legal Name Avanir Pharmaceuticals, Inc.
Funding Insights of Avanir
- Total Rounds 1
- Last Round Debt – Conventional — $30M
- First Round $30M
(Jun 2012)
- Investors Count 2
All 1 funding rounds of Avanir with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | $30M | Debt – Conventional | – | – |
3 investors in total: 3 institutional.
Investors in Avanir
Avanir has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Otsuka and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Generic pharmaceuticals and nutraceuticals are manufactured and marketed by Otsuka. | 1921 | otsuka.com | Chiyoda City, Japan |
Investor details for Avanir
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avanir
98 people are tracked at Avanir (42 in leadership, 17 in board & advisors, 39 in team).
| Name | Role | Group |
|---|---|---|
Wa El Hashad | CEO & President | Leadership |
Yuko Makino | CFO | Leadership |
Tatsuo Higuchi | CEO, President, Representative Director | Leadership |
Noriko Tojo | Executive Director | Leadership |
Shuichi Takagi | Executive Director | Leadership |
Yoshiro Matsuo | Executive Deputy President & Director | Leadership |
Makoto Inoue | Representative Director & COO | Leadership |
Chikako Usami | VP, Pharmaceutical Business Division Project Coordinator | Leadership |
Masayuki Kobayashi | Executive Director | Leadership |
Koichi Shiraishi | VP, Nutraceuticals Business, China | Leadership |
Titus Divala M.D. Fcphp | Director, Global Clinical Development | Leadership |
Masayuki Sato | VP & Director, Portfolio Management Office & Public Relations | Leadership |
Naoshi Satou | SVP & Associate GM, Nutraceuticals Division & Director, Social Health Relations Department | Leadership |
Mohamed Saleh | Quality System Operation Head | Leadership |
Yoshimi Kuroiwa | 創薬モダリティ研究所 所長 Head Of Department, Department Of Drug Modality Development | Leadership |
Tomoyuki Murata | Director, Global Compliance | Leadership |
Ryo Harima | VP, Deputy GM, Production & Purchasing | Leadership |
Takeshi Watanabe | VP, Director, Department of Business Development | Leadership |
Lyo Inuyama | EVP & Director, Medical Affairs, PV | Leadership |
Yoshihiro Yoshinaga | VP & Director, Regulatory Affairs Department & Administration Department | Leadership |
78 more people are available in the full profile.
Complete people profiles for Avanir
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Avanir
3 dated milestones of Avanir across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Avanir is founded.
- Funding First funding round of $30.0M.
- Exit Acquired by Otsuka.
Competitors of Avanir
Avanir operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Sana Biotechnology, Karuna Therapeutics and Kriya Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders |
Detailed competitors of Avanir
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Avanir
Websites that share an audience with Avanir (avanir.com).
Websites whose visitors overlap most with Avanir. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acorda.com | 100% | – | #13,560,187 | View details | |
| medapharma.us | 76% | – | – | View details | |
| dicerna.com | 75% | – | – | View details | |
| amgen.com | 74% | 495.4K | #116,434 | View details | |
| genzyme.com | 74% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Avanir
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Avanir
Complete news archive for Avanir
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Avanir
10 companies that operate in the same segment as Avanir (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Avanir
Avanir was founded in 1988 and raised its 1st funding round 24 years after it was founded.
Avanir is headquartered in Aliso Viejo, United States. It is registered at Aliso Viejo, California, United States.
Wa El Hashad is the current CEO of Avanir.
Avanir Pharmaceuticals was established in 1988 in Aliso Viejo, United States, as a biopharmaceutical entity. Focus is placed on acquiring, developing, and commercializing treatments for central nervous system disorders. Nuedexta, approved by the FDA for pseudobulbar affect, and Onzetra Xsail, for acute migraine treatment in adults, are marketed. AVP-786 is under clinical development for conditions including Alzheimers disease, depression, and schizophrenia.
Avanir's top competitors include Jazz Pharmaceuticals, Neurocrine and Biohaven Pharmaceutical.
Avanir has 3 investors. Key investors include SVB, Otsuka, and Oxford Finance.
Avanir operates through Avanir Pharmaceuticals, Inc..
Yes. Avanir was acquired by Otsuka in December 2014.